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Abstract
Objective To assess the costs and health effects of
tuberculosis control interventions in Africa and South
East Asia in the context of the millennium
development goals.
Design Cost effectiveness analysis based on an
epidemiological model.
Setting Analyses undertaken for two regions classified
by WHO according to their epidemiological
grouping—Afr-E, countries in sub-Saharan Africa with
very high adult and high child mortality, and Sear-D,
countries in South East Asia with high adult and high
child mortality.
Data sources Published studies, costing databases,
expert opinion.
Main outcome measures Costs per disability adjusted
life year (DALY) averted in 2000 international dollars
($Int).
Results Treatment of new cases of smear-positive
tuberculosis in DOTS programmes cost $Int6-8 per
DALY averted in Afr-E and $Int7 per DALY averted
in Sear-D at coverage levels of 50-95%. In Afr-E,
adding treatment of smear-negative and
extra-pulmonary cases at a coverage level of 95% cost
$Int95 per DALY averted; the addition of DOTS-Plus
treatment for multidrug resistant cases cost $Int123.
In Sear-D, these costs were $Int52 and $Int226,
respectively. The full combination of interventions
could reduce prevalence and mortality by over 50% in
Sear-D between 1990 and 2010, and by almost 50%
between 2000 and 2010 in Afr-E.
Conclusions DOTS treatment of new smear-positive
cases is the first priority in tuberculosis control,
including in countries with high HIV prevalence.
DOTS treatment of smear-negative and
extra-pulmonary cases and DOTS-Plus treatment of
multidrug resistant cases are also highly cost effective.
To achieve the millennium development goal for
tuberculosis control, substantial extra investment is
needed to increase case finding and implement
interventions on a wider scale.
Introduction
In developing countries, tuberculosis is second only to
HIV/AIDS as the most common cause of adult death
and is a top public health problem almost everywhere.
The United Nations millennium development goals
include targets for tuberculosis control, now adopted
and extended by the international Stop TB Partner-
ship. The targets include reversing tuberculosis
incidence by 2015, halving tuberculosis prevalence and
mortality by 2015 (compared with 1990), and diagnos-
ing 70% of new smear-positive cases and curing 85% of
these cases by 2015 (see bmj.com).1
For many countries, the targets will not be achieved
at current rates of progress.2 This means that an
important question is whether the correct mix of inter-
ventions is currently being used, and what strategies
should be scaled up if current international efforts to
raise extra funds for health care are successful. Cost
and cost effectiveness analyses can help with these
decisions.
The main interventions recommended to control
tuberculosis are short course treatment with first line
drugs for drug-susceptible tuberculosis (smear-positive
pulmonary, smear-negative pulmonary, and extra-
pulmonary) within the framework of the DOTS
strategy, and treatment of cases with multidrug
resistant tuberculosis with longer and more complex
drug regimens that include second line as well as first
line drugs within the framework of the DOTS-Plus
strategy (see bmj.com for details).
To date, most economic studies of tuberculosis
interventions in developing countries have evaluated
short course treatment for drug susceptible, smear-
positive pulmonary tuberculosis,3–5 since this is the
most infectious form of the disease. Most studies are
from Africa,6 although Asia has the highest burden of
tuberculosis. Two studies have also reported the cost
effectiveness of treating smear-negative cases.7 8 One
study, from Peru, reports treatment for multidrug
resistant tuberculosis with first line and second line
drugs.9
Most studies did not assess the impact of interven-
tions on transmission, and most used indicators of
effectiveness that are specific to tuberculosis control,
preventing the cost effectiveness being compared with
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that of interventions for other diseases. Moreover,
interventions have generally been considered individu-
ally, not in combination.
In this paper we address the question of what are
the costs and effects of treatment of new smear-positive
cases and of new smear-negative and extra-pulmonary
cases in DOTS programmes, and of DOTS-Plus
treatment for multidrug resistant cases that have not
responded to first line treatments, both singly and in
combination. Our analysis includes assessment of the
impact of interventions on transmission, a generic
measure of effectiveness, and covers Asia as well as
Africa.
Methods
General approach
We evaluated interventions for two particular regions
classified by the World Health Organization: Afr-E,
countries in sub-Saharan Africa with very high adult
and high child mortality, and Sear-D, countries in
South East Asia with high adult and high child mortal-
ity.10 (See bmj.com for existing levels of tuberculosis
control globally and these two regions.)
Interventions run for the 10 years 2000-9. We
included all benefits accruing during the period 2000-
100. We evaluated the three standard levels of
geographical coverage—50%, 80%, and 95%—which in
this case mean the percentage of eligible cases living in
areas where treatment is available. We assessed costs
from a societal perspective, and used a population
model to translate disease-specific results into a
generic measure of health effects. See Evans et al for
details of the standardised analytical approach.10
Interventions
We restricted our analysis to four interventions:
Minimal DOTS—Treatment in DOTS programmes
for new smear-positive cases only. We assume the per-
centage of cases diagnosed and treated in areas
covered by DOTS increases linearly from year 2000
levels to the WHO target of 70% in 2009 and the cure
rate is at the WHO target level of 85% from 2000 to
2009. In areas not covered by DOTS, we assume no
cases are treated. In all areas, no cases are treated from
2010 onwards.
Full DOTS—As for minimal DOTS plus treatment
of smear-negative and extra-pulmonary cases in DOTS
programmes. We assume the percentage of cases diag-
nosed and cured is the same as for smear-positive
cases.
Minimal DOTS plus resistant cases—As for minimal
DOTS plus treatment of multidrug resistant cases in
DOTS-Plus programmes with an 18 month regimen
that includes first and second line drugs. We assume
patients are tested for multidrug resistance after failing
treatment with the short course of first line drugs. We
assume the cure rate to vary from 48% (baseline analy-
sis) to 70% (sensitivity analysis).9
Full combination—As for full DOTS plus DOTS-Plus
treatment for multidrug resistant tuberculosis as
defined above.
The maximum scale at which we considered each
intervention is much greater than the level of tubercu-
losis control efforts in 2003.
Estimating health effects
We estimated health effects in three steps. Firstly, we
calibrated a published tuberculosis-HIV model11 12 to
produce tuberculosis incidence, prevalence, and
mortality for each region that matched those observed
between 1950 and 2000 (see bmj.com for details).
Secondly, we used the calibrated tuberculosis-HIV
model to project incidence, prevalence, and mortality
for the period 2000 to 2100 for the base case of no
interventions, and then for each of the intervention
scenarios.
Thirdly, we used the population model PopMod13
to combine the projected incidence, prevalence, and
mortality data with the standard health state valua-
tions14 to estimate the population impact of the differ-
ent interventions in terms of healthy years lived.10 We
ran the model for the length of time necessary for all
people affected by the interventions to have died. The
Table 1 Annual numbers of patients treated, total costs in international dollars ($Int), total effects, and average and incremental cost
effectiveness for various tuberculosis control interventions in the Afr-E region
Intervention*
Coverage
level
No of patients treated (millions)
($Int millions)
Yearly DALYs
averted (millions)
New
smear-positive
cases
New smear-negative
and extra-pulmonary
cases
Multidrug
resistant
cases Average Incremental†
Minimal DOTS 50% 0.33 NA NA 146.3 23.6 6.2 6.2
80% 0.52 NA NA 262.6 37.7 7.0 8.2
95% 0.62 NA NA 366.3 44.8 8.2 14.7
Full DOTS 50% 0.32 0.27 NA 242.4 24.9 9.7 NA
80% 0.52 0.43 NA 439.6 39.9 11.0 NA
95% 0.62 0.51 NA 612.2 47.4 12.9 94.5
Minimal DOTS
plus resistant
cases
50% 0.32 NA 0.01 184.1 24.1 7.6 NA
80% 0.51 NA 0.02 343.4 38.6 8.9 NA
95% 0.61 NA 0.03 495.9 45.9 10.8 NA
Full combination 50% 0.32 0.27 0.01 279.1 25.5 11.0 NA
80% 0.51 0.43 0.02 518.6 40.8 12.7 NA
95% 0.61 0.51 0.03 739.4 48.4 15.3 123.2
Values are averages over the 10 year evaluation period. Costs are given in international dollars (a hypothetical unit of currency that has the same purchasing power
that the US$ has in the United States at a given point in time) and can be converted into US$ for a reference country in a region. For example, cost estimates in
Afr-E in $Int should be divided by 4.5 to obtain US$ cost estimates for Kenya. Details of this approach are discussed elsewhere.18
NA=Not applicable.
Cost per DALY averted ($Int)
*See methods section for details of interventions.
†Incremental costs per DALY averted measure the increase in cost divided by the increase in effects when a new intervention is added to an existing intervention.
Values are not shown for interventions that are dominated (more costly but less effective than others).
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difference between the healthy years lived in each
intervention scenario and the no-intervention scenario
is the health gain of the intervention, or the number of
disability adjusted life years (DALYs) averted.
Estimating costs
We based our estimates of the resources required—
diagnostic tests, drug use, health centre visits for super-
vision and monitoring, and hospitalisation—for each
intervention on WHO treatment protocols and expert
opinion. We combined unit costs with patterns of
resource use to estimate the cost per patient treated,
and calculated total patient costs as the cost per patient
treated multiplied by the number of patients treated.
We estimated the costs of running the programmes
using a standardised approach.10 All costs are reported
in international dollars ($Int) for the year 2000, and
the conversion from $Int to US$ is explained
elsewhere.10
Results
The tuberculosis model replicated the strong increase
in the incidence of infectious disease in Afr-E from
around 1990, with an annual growth rate of about 10%
between 1990 and 2000. In Sear-D, the tuberculosis
model estimates an annual decline in incidence of 1%
in the same period.
Intervention effects
Tables 1 and 2 show the health effects, costs, and cost
effectiveness of the different interventions in Afr-E and
Sear-D. When only smear-positive cases are treated in
DOTS programmes and the geographical coverage
level is 95%, an average of 0.62 million people are
treated in Afr-E and 1.38 million in Sear-D each year.
The annual cost averages $Int366m in Afr-E and
$Int536m in Sear-D. The total number of DALYs
averted per year averages 44.8 million in Afr-E and
76.6 million in Sear-D. Adding treatment of smear-
negative and extra-pulmonary cases or of multidrug
resistance cases increases costs considerably but
increases the DALYs averted only slightly. Increasing
the coverage level from 50% to 95% roughly doubles
both costs and effects for each of the four interventions
considered.
In both regions, treating only smear-positive cases
is the most cost effective intervention, with an average
cost per DALY averted of ≤ $Int8 at all coverage levels.
The next most cost effective intervention in both
regions is treatment for both smear-positive and
smear-negative and extra-pulmonary cases at a
coverage level of 95%, at a cost per DALY averted of
$Int95 in Afr-E and $Int52 in Sear-D. This is followed
by implementing the full combination of interventions,
including treatment for multidrug resistant tuberculo-
sis, at a cost per DALY averted of $Int123 in Afr-E and
$Int226 in Sear-D.
Treating only smear-positive cases at a coverage
level of 50% would be introduced first for Afr-E
(figure). With more resources, coverage would be
expanded to 80% and then to 95%. With yet more
resources, treatment of smear-negative and extra-
pulmonary cases would be introduced, followed by the
addition of treatment for multidrug resistant cases. The
expansion path is similar in Sear-D.
Table 2 Annual numbers of patients treated, total costs in international dollars ($Int), total effects, and average and incremental cost
effectiveness for various tuberculosis control interventions in the Sear-D region
Intervention*
Coverage
level
No of patients treated (millions)
Yearly costs
($Int millions)
Yearly DALYs
averted (millions)
New
smear-positive
cases
New smear-negative
and extra-pulmonary
cases
Multidrug
resistant
cases Average Incremental†
Minimal DOTS 50% 0.73 NA NA 293.1 40.3 7.3 NA
80% 1.16 NA NA 442.6 64.5 6.9 6.9
95% 1.38 NA NA 536.4 76.6 7.0 7.8
Full DOTS 50% 0.72 0.25 NA 473.7 43.9 10.8 NA
80% 1.15 0.40 NA 731.7 70.2 10.4 NA
95% 1.37 0.47 NA 883.4 83.4 10.6 51.6
Minimal DOTS
plus resistant
cases
50% 0.72 NA 0.10 500.4 41.3 12.1 NA
80% 1.15 NA 0.16 773.4 66.0 11.7 NA
95% 1.36 NA 0.18 932.6 78.4 11.9 NA
Full combination 50% 0.71 0.25 0.10 677.4 44.8 15.1 NA
80% 1.14 0.39 0.15 1056.7 71.6 14.7 NA
95% 1.35 0.47 0.18 1272.7 85.1 15.0 226.4
Values are averages over the 10 year evaluation period. Costs are given in international dollars (a hypothetical unit of currency that has the same purchasing power
that the US$ has in the United States at a given point in time) and can be converted into US$ for a reference country in a region. For example, cost estimates in
Sear-D in $Int should be divided by 5.2 to obtain US$ cost estimates for India. Details of this approach are discussed elsewhere.18
NA=Not applicable.
Cost per DALY averted ($Int)
*See methods section for details of interventions.
†Incremental costs per DALY averted measure the increase in cost divided by the increase in effects when a new intervention is added to an existing intervention.
Values are not shown for interventions that are dominated (more costly but less effective than others).
Yearly DALYs averted (millions)
Ye
ar
ly
 c
os
ts
 ($
In
t m
ill
io
ns
)
0 10 20 30 40 50
0
400
600
800
Full combination (95% coverage)
Full DOTS (95% coverage)
Minimal DOTS
(80% coverage)
Minimal DOTS
(50% coverage)
200
Minimal DOTS
(95%
coverage)
Expansion path for tuberculosis interventions in Afr-E region
according to average and incremental cost effectiveness. (See
methods for description of interventions)
Papers
1366 BMJ VOLUME 331 10 DECEMBER 2005 bmj.com
In Sear-D, our model suggests that implementing
the full combination of interventions could reduce
tuberculosis prevalence and mortality by 71% and 64%
respectively between 1990 and 2010. In Afr-E
prevalence and mortality increase substantially
between 1990 and 2000, because of the HIV epidemic,
but could fall by 50% and 40% respectively between
2000 and 2010.
Sensitivity and uncertainty analyses had little
impact on our cost per DALY averted results for Afr-E
or Sear-D (see bmj.com).
Discussion
Since the early 1990s, short course drug treatment for
new smear-positive cases of tuberculosis has been pro-
moted as one of the most cost effective healthcare
interventions available, with a reported cost per DALY
averted of US$1-3.3 Our updated analysis, covering
countries with some of the highest rates of tuberculosis
infection in sub-Saharan Africa and South East Asia,
supports this result, with the cost per DALY averted at
around $Int8 ( < US$2) in both regions. The addition
of the other interventions that we considered—
treatment of smear-negative and extra-pulmonary
cases in DOTS programmes and treatment of
multidrug resistant cases in DOTS-Plus
programmes—is also highly cost effective compared
with commonly used benchmarks.
Limitations of study
Some limitations are related to the general approach
to cost effectiveness analysis, and are discussed
elsewhere.10 Limitations that are specific to this analysis
for tuberculosis include the fact that we assumed that
key model parameters such as tuberculosis transmis-
sion rates are the same across regions. Our assumption
that multidrug resistant tuberculosis and drug suscep-
tible tuberculosis are equally transmissible contrasts
with the more conservative range of assumptions con-
sidered in an earlier study.9 A further limitation is that
we may have underestimated the costs of increasing
the percentage of tuberculosis cases that are treated in
DOTS programmes. Our study results may not be
directly generalisable to other settings. However,
studies for other regions using similar methods show
similar results.15
Strengths of our study include the use of a tubercu-
losis model that has been widely applied,12 considera-
tion of combinations of interventions, inclusion of
transmission in the analysis, use of a generic measure
of effectiveness, and testing of important assumptions
through sensitivity analyses.
Implications of results
Our results have three major policy implications.
Firstly, they reinforce the principle that treatment of
smear-positive cases in DOTS programmes must be
the basis of any tuberculosis control strategy, as has
become standard practice in almost all control
programmes.
Secondly, they show that there is a strong economic
case for treating smear-negative and extra-pulmonary
cases in DOTS programmes and for treating multidrug
resistant cases in DOTS-Plus programmes.
Finally, our study shows that substantial scaling up
of all three interventions is needed in the next 10 years
if the millennium development goal and related targets
for tuberculosis control are to be reached. In particular,
the case detection rate must be improved so that many
more tuberculosis cases are diagnosed and successfully
treated.
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Time trends in primary resistance to HIV drugs in the
United Kingdom: multicentre observational study
UK Group on Transmitted HIV Drug Resistance
Abstract
Objective To examine whether the level of primary
resistance to HIV drugs is increasing in the United
Kingdom.
Design Multicentre observational study.
Setting All virology laboratories in the United
Kingdom carrying out tests for HIV resistance as part
of routine clinical care.
Participants 2357 people infected with HIV who
were tested for resistance before receiving
antiretroviral therapy.
Main outcome measure Prevalence of drug
resistance on basis of the Stanford genotypic
interpretation system.
Results Over the study period (February 1996 to May
2003), 335 (14.2%, 95% confidence interval 12.8% to
15.7%) samples had mutations that conferred
resistance to one or more antiretroviral drugs (9.3%
high level resistance, 5.9% medium level resistance).
The prevalence of primary resistance has increased
markedly over time, although patterns are specific to
drug class; the largest increase was for non-nucleoside
reverse transcriptase inhibitors. In 2002-3, the
prevalence of resistance to any antiretroviral drug, to
nucleoside or nucleotide reverse transcriptase
inhibitors, to non-nucleoside reverse transcriptase
inhibitors, or to protease inhibitors was 19.2% (15.7%
to 23.2%), 12.4% (9.5% to 15.9%), 8.1% (5.8% to
11.1%), and 6.6% (4.4% to 9.3%), respectively. The risk
of primary resistance was only weakly related to most
demographic and clinical factors, including ethnicity
and viral subtype.
Conclusions The United Kingdom has one of the
highest reported rates of primary resistance to HIV
drugs worldwide. Prevalence seems still to be
increasing and is high in all demographic subgroups.
Introduction
Combination antiretroviral therapy has improved the
prognosis of patients infected with HIV. Concerns are
mounting that a secondary epidemic of drug resistant
virus would render treatment less effective.1–3 We
describe a national surveillance scheme for HIV drug
resistance on the basis of routine clinical samples. Of
about 13 000 samples tested between 1996 and 2003,
over 2300 were from patients who had never received
antiretroviral therapy. We used these data to analyse
the epidemiology of primary drug resistance in the
United Kingdom, including temporal trends and asso-
ciations with demographic and clinical factors.
Methods
The UK HIV drug resistance database is a repository
of resistance tests carried out as part of routine care in
the United Kingdom. The tests in our analysis were
based on DNA sequencing of the pol gene. All
sequences encompassed at least codons 4-99 of the
protease gene and 34-234 of the reverse transcriptase
gene. See bmj.com for data entered. Subtype was
assigned using the STAR algorithm.4
We classified the patients’ treatment status from
several sources (see bmj.com). We defined a test as
relating to recent infection if the patient was enrolled
in the UK register of HIV seroconverters,5 and the
sample was taken within 18 months of a negative HIV
antibody test result or other laboratory test result indi-
cating acute infection.
We verified the information on therapy status for a
sample of patients with one or two major mutations6
and all patients with three or more major mutations.
Information on antiretroviral therapy was incorrect in
26 (18%) of the 142 cases checked; we excluded these
patients from the analysis.
The analysis includes all resistance tests on patients
aged over 16 years who were naive to antiretroviral
therapy. We used the Stanford HIVdb algorithm to
assess the level of resistance to drugs7: a matrix of scores
for each drug-mutation combination are summed
across all mutations in the sample, and drug susceptibil-
ity is classified as “sensitive” (total score < 15), “interme-
diate” (15-29), or “resistant” ( ≥ 30). We refer to the last
two categories as medium level and high level resistance.
Statistical analysis
We derived confidence intervals for proportions using
the “exact” method. Logistic regression analysis was
used to examine the association between demographic
and clinical factors and the prevalence of resistance,
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